Fosigotifator (ABBV-CLS-7262): A Comprehensive Monograph on an eIF2B Activator in Clinical Development for Neurodegenerative and Psychiatric Disorders

Executive Summary

Fosigotifator (ABBV-CLS-7262) is a first-in-class, orally bioavailable, central nervous system (CNS)-penetrant small molecule being developed as an activator of eukaryotic initiation factor 2B (eIF2B). This enzyme is a critical regulator of the Integrated Stress Response (ISR), a fundamental cellular pathway implicated in the pathophysiology of numerous age-related and neurodegenerative diseases. The drug is the product of a strategic collaboration between Calico Life Sciences, a subsidiary of Alphabet focused on the biology of aging, and the global biopharmaceutical company AbbVie. This partnership has pursued a novel, pathway-centric development strategy, investigating Fosigotifator across three distinct therapeutic areas that share the common mechanistic link of chronic ISR activation: amyotrophic lateral sclerosis (ALS), Vanishing White Matter (VWM) disease, and Major Depressive Disorder (MDD).

The clinical development program for Fosigotifator has yielded a complex and nuanced profile. The largest and most advanced study, Regimen F of the HEALEY ALS Platform Trial, failed to meet its primary endpoint of slowing disease progression at the pre-specified primary dose. This outcome represented a significant setback for the program. However, a pre-specified analysis of an exploratory high dose revealed statistically significant and potentially clinically meaningful signals, demonstrating a marked slowing in the decline of both upper and lower extremity muscle strength. This finding, coupled with the drug's exceptionally benign safety profile across all studies, suggests that the primary dose was suboptimal and provides a clear, albeit challenging, path forward for the ALS indication.

The strongest scientific rationale for Fosigotifator lies in its application for VWM disease, an ultra-rare genetic leukoencephalopathy directly caused by mutations in the eIF2B enzyme. The drug's mechanism is a perfect molecular fit for correcting the underlying pathology of this devastating condition. In recognition of this strong scientific premise and the high unmet need, the U.S. Food and Drug Administration (FDA) recently selected Fosigotifator for its Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program, a move that could significantly accelerate its development. A Phase 1b/2 trial in VWM patients is currently ongoing and represents the program's highest probability of success.

The expansion into MDD is a more speculative but scientifically grounded exploration of the ISR's role in psychiatric disorders. An initial Phase 1 study in this population has been completed. Overall, Fosigotifator represents a pioneering therapeutic approach targeting a fundamental disease pathway. Its future now hinges on the ability of its developers to successfully confirm the high-dose efficacy signals in a new ALS trial and, most critically, on the outcome of the ongoing trial in VWM disease, which could provide the ultimate validation for this novel mechanism of action.

Molecular Profile and Pharmaceutical Formulation

A precise understanding of the investigational asset requires a clear distinction between the active pharmaceutical ingredient (API) and the formulated drug product used in clinical trials. The development of ABBV-CLS-7262 from the parent compound Fosigotifator reflects a deliberate pharmaceutical strategy to create a viable oral therapeutic with optimized biopharmaceutical properties.

Identification and Nomenclature

The investigational drug administered in all clinical studies is a complex salt formulation officially designated Fosigotifator sodium tromethamine.[1] This formulation is identified by the development code ABBV-CLS-7262 and is composed of three distinct molecular components: the parent compound Fosigotifator, a sodium ion, and tromethamine (also known as Tris(hydroxymethyl)aminomethane).[1]

The active pharmaceutical ingredient responsible for the therapeutic effect is Fosigotifator.[1] Fosigotifator is a prodrug designed to modulate the integrated stress response pathway and has been patented by AbbVie and Calico Life Sciences.[2] The use of a sodium tromethamine salt is a common and effective pharmaceutical formulation technique. The parent molecule, Fosigotifator, contains a dihydrogen phosphate group, making it an acidic compound. Such molecules often exhibit poor aqueous solubility and chemical stability, which are significant barriers to developing an effective oral medication. Tromethamine is a biologically compatible organic amine that acts as a buffer, increasing the pH of the local microenvironment to enhance the solubility and stability of acidic drug substances. Therefore, the creation of ABBV-CLS-7262 is a critical formulation step to ensure the compound has the necessary properties for consistent oral absorption and delivery to the site of action.

Chemical Structure and Physicochemical Properties

The distinct chemical identities of the formulation and the parent compound are detailed below. The computed physicochemical properties are consistent with those of a molecule designed for oral bioavailability and the potential to cross the blood-brain barrier, a prerequisite for treating CNS disorders.

ABBV-CLS-7262 (Fosigotifator sodium tromethamine):

• Molecular Formula: $C_{29}H_{37}Cl_{2}F_{2}N_{3}NaO_{12}P$ [1]
• Molecular Weight: 782.5 g/mol [1]
• IUPAC Name: sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;amino]-2-bicyclo[2.2.2]octanyl]oxymethyl hydrogen phosphate [1]

Fosigotifator (Parent Compound):

• Molecular Formula: $C_{25}H_{27}Cl_{2}F_{2}N_{2}O_{9}P$ [2]
• Molecular Weight: 639.37 g/mol [3]
• **IUPAC Name:**amino]-2-bicyclo[2.2.2]octanyl]oxymethyl dihydrogen phosphate [3]

The key identifiers and properties for both the clinical formulation and the parent compound are summarized in Table 1.

Identifier Type	ABBV-CLS-7262 (Formulation)	Fosigotifator (Parent Compound)
Primary Name	Fosigotifator sodium tromethamine	Fosigotifator
DrugBank ID	DB18407 1	DB19409 3
CAS Number	2945073-88-9 1	2415715-84-1 2
UNII	BN9FN5629V 1	3FQ7XKK8AY 3
PubChem CID	166177193 1	153563259 1
Molecular Formula	$C_{29}H_{37}Cl_{2}F_{2}N_{3}NaO_{12}P$ 1	$C_{25}H_{27}Cl_{2}F_{2}N_{2}O_{9}P$ 3
Molecular Weight	782.5 g/mol 1	639.37 g/mol 2
logP	0.89 5	1.11 6
pKa (Strongest Acidic)	1.43 5	Not available
Hydrogen Bond Acceptors	15 1	11 3
Hydrogen Bond Donors	7 1	4 3
Polar Surface Area	242 Ų 1	162.46 Ų 6

Scientific Rationale and Mechanism of Action

The development of Fosigotifator is predicated on a deep understanding of the Integrated Stress Response (ISR), a fundamental cellular pathway whose chronic activation is increasingly recognized as a key driver of pathology in a wide range of diseases. Fosigotifator represents a targeted therapeutic strategy designed to restore homeostasis by directly modulating a central node in this pathway.

The Integrated Stress Response (ISR) in Disease Pathophysiology

The ISR is a highly conserved signaling network that cells activate in response to a variety of physiological and pathological stressors, including the accumulation of misfolded proteins, viral infections, amino acid deprivation, and oxidative stress.[8] The central event of the ISR is the phosphorylation of the alpha subunit of eukaryotic translation initiation factor 2 (eIF2). This phosphorylation converts eIF2 from an active substrate into a competitive inhibitor of its own guanine nucleotide exchange factor, eIF2B.[8] The inhibition of eIF2B activity leads to a rapid and global reduction in the synthesis of new proteins, which allows the cell to conserve energy and resources while it attempts to resolve the source of the stress.[10]

While this response is adaptive and protective in the short term, persistent or chronic activation of the ISR becomes maladaptive and contributes to cellular dysfunction and death.[8] This chronic ISR activation is a key feature in the pathophysiology of several major human diseases.

• In neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), the accumulation of misfolded proteins, such as TDP-43, is a major cellular stressor that triggers the ISR. The persistent activation of the ISR is believed to promote the formation of pathological TDP-43-containing stress granules, which are thought to be precursors to the toxic protein inclusions that are a defining hallmark of ALS pathology in over 97% of cases.[11]
• In Vanishing White Matter (VWM) disease, the connection is even more direct and causal. VWM is a rare genetic disorder caused by mutations in any of the five genes that encode the subunits of the eIF2B enzyme itself.[9] These mutations result in a structurally compromised eIF2B complex with reduced enzymatic activity, leading to a state of chronic ISR activation. This dysregulation is particularly damaging to oligodendrocytes and astrocytes in the brain, causing the progressive destruction of cerebral white matter that defines the disease.[9]

Fosigotifator as an eIF2B Activator

Fosigotifator is a potent, selective, and CNS-penetrant small molecule designed to function as a direct activator of the eIF2B enzyme.[6] Its mechanism of action is to bind to the eIF2B complex and stabilize it in a more active conformation. By doing so, Fosigotifator directly counteracts the inhibitory effects of stress-induced eIF2 phosphorylation, effectively "releasing the brake" on protein synthesis.[10] This modulation of the ISR is hypothesized to confer therapeutic benefits through several downstream effects:

• Restoration of Protein Synthesis: By reactivating eIF2B, the drug allows for the resumption of normal protein translation, which is essential for neuronal health and function.[10]
• Dissolution of Stress Granules: In the context of ALS, preclinical evidence suggests that inhibiting the ISR with an eIF2B activator can dissolve pre-formed TDP-43 stress granules, which may prevent their conversion into permanent, toxic aggregates.[11]
• Correction of Genetic Defects: In VWM disease, Fosigotifator is designed to directly address the root cause of the disease by increasing the residual activity of the mutated eIF2B enzyme complexes, thereby normalizing the ISR and protecting the brain's white matter.[14]

This "pathway-centric" approach to drug development is a hallmark of the Calico/AbbVie strategy. Rather than targeting a single disease, they have identified a fundamental biological pathway—the ISR—that is dysregulated across multiple, seemingly unrelated conditions. By developing a molecule that modulates this central pathway, they have created a potential "pipeline-in-a-product," where a single asset can be tested in diverse indications like ALS, VWM, and even Major Depressive Disorder, all of which have been linked to chronic cellular stress.[9] This high-risk, high-reward strategy aims to validate the ISR as a master therapeutic target in human disease.

Preclinical Validation

The decision to advance Fosigotifator into clinical trials was supported by compelling preclinical data. The most direct evidence came from a mouse model of VWM disease, which carries mutations analogous to those found in human patients. In these animals, treatment with Fosigotifator produced two critical outcomes:

1. Target Engagement: The drug successfully blunted the persistent activation of the ISR in the brain and spinal cord, demonstrating that it could reach its target in the CNS and exert its intended biochemical effect.[9]
2. Functional Improvement: This biochemical effect translated into a tangible therapeutic benefit, as the treated mice showed corrected coordination and movement problems compared to untreated animals.[9]

Further evidence for the neuroprotective potential of ISR modulation came from models of optic nerve crush injury. In this paradigm, trauma to the optic nerve induces a strong ISR in retinal ganglion cells, leading to their death. Treatment with eIF2B activators was shown to be highly protective, significantly increasing the number of surviving retinal neurons after injury.[17] These preclinical results provided strong proof-of-concept for the therapeutic hypothesis and justified the initiation of a comprehensive clinical development program.

Clinical Pharmacology and Pharmacokinetics

A rigorous and comprehensive Phase 1 program was conducted to characterize the behavior of ABBV-CLS-7262 in humans. This program was notable for its proactive approach, addressing key development questions such as CNS penetration, target engagement, and special population pharmacokinetics early in the process. This strategy established a strong foundation of data that de-risked the transition to later-stage, more complex clinical trials.

Human Pharmacokinetics and Safety in Healthy Volunteers

The first-in-human evaluation of ABBV-CLS-7262 was a multi-part Phase 1 study that enrolled 125 healthy subjects, with an additional 33 subjects receiving a placebo.[10] The study assessed the safety and pharmacokinetics of the drug following oral administration of both single and multiple ascending doses for a duration of up to 14 days.[10]

The results established a very favorable safety and tolerability profile. All adverse events (AEs) reported were mild to moderate in severity, and critically, no dose-dependent patterns of AEs or clinically significant laboratory abnormalities were identified.[10] This benign safety profile indicated a wide therapeutic window and supported the investigation of the drug in further studies across a broad range of doses.[10] To fully characterize the drug's disposition, a dedicated study in healthy male volunteers using a radiolabeled version ($[^{14}C]$ ABBV-CLS-7262) was also conducted (NCT06425003) to precisely determine its absorption, distribution, metabolism, and excretion (ADME) properties.[21]

Special Population Pharmacokinetics and Drug Interactions

The development program proactively investigated factors that could influence the drug's behavior in diverse patient populations and clinical settings.

• Food Effect: A key part of the first-in-human study evaluated the effect of food on the drug's absorption. When ABBV-CLS-7262 was administered with a high-fat meal, its safety, tolerability, and pharmacokinetic profile were found to be similar to administration in a fasting state.[10] This lack of a significant food effect is a valuable practical attribute, as it simplifies dosing instructions for patients and eliminates the need for dietary restrictions around the time of administration.
• Ethnic Sensitivity: To support future global clinical trials, a dedicated Phase 1 Asian PK study was conducted to compare the pharmacokinetics of ABBV-CLS-7262 in healthy Japanese and Han Chinese subjects with those in healthy Western subjects.[8] The study found that the key pharmacokinetic exposure parameters, maximum concentration ($C_{max}$) and area under the curve (AUC), were comparable across all three populations. The ratios of $C_{max}$ and AUC for Japanese versus Western subjects were 1.152 and 0.875, respectively, while the ratios for Chinese versus Western subjects were 1.110 and 1.065, respectively.[8] These results demonstrated that no meaningful differences in drug exposure exist, leading to the important conclusion that dose adjustments are not required for Asian populations.[8]
• Drug-Drug Interactions (DDI): A Phase 1, open-label, single-group assignment study (NCT05763459) was completed to evaluate the potential for drug-drug interactions between ABBV-CLS-7262 and two commonly used probe substrates, rosuvastatin and digoxin.[22] While the specific results of this study are not publicly available, its execution demonstrates a thorough characterization of the drug's interaction potential. Furthermore, the exclusion criteria for the HEALEY ALS trial specified that patients could not be taking certain inhibitors or inducers of cytochrome P450 enzymes, which indicates that this is a known metabolic pathway for the compound.[23]

Evidence of Target Engagement and CNS Penetration

For any drug being developed for a neurological disorder, two fundamental questions must be answered early and definitively: does the drug cross the blood-brain barrier to reach its target, and does it engage that target in a meaningful way in humans? The clinical pharmacology program for ABBV-CLS-7262 was designed to provide clear answers to both.

Fosigotifator is explicitly described as a CNS-penetrant small molecule.[10] This crucial property was confirmed directly in human studies, where the drug was measured in the cerebrospinal fluid (CSF) of healthy volunteers. The concentrations achieved in the CSF were found to be at levels predicted to be pharmacologically active and sufficient to fully activate the eIF2B target enzyme.[17]

In addition to confirming CNS penetration, the program also provided direct evidence of pharmacodynamic activity and target engagement. Blood cells were collected from trial participants who had received ABBV-CLS-7262, and two key biomarkers of ISR pathway activity were measured. The results showed that the drug produced its expected biological effects: it enhanced the enzymatic activity of eIF2B and, as a downstream consequence, suppressed the expression of TRIB3, a known ISR stress gene.[17] The successful demonstration of both CNS penetration and target engagement in these early human studies were critical de-risking milestones that provided strong confidence to proceed with large-scale efficacy trials in patient populations.

Clinical Development Program and Efficacy Analysis

The clinical development strategy for Fosigotifator has been ambitious, spanning multiple therapeutic areas to test the broad potential of ISR modulation. The program has progressed from foundational studies in healthy volunteers to large, late-stage trials in patient populations, most notably in ALS. The following table provides a consolidated overview of the key clinical trials conducted to date.

NCT Identifier	Study Phase	Indication(s)	Status	Brief Description/Purpose
NCT04948645	Phase 1	Amyotrophic Lateral Sclerosis (ALS)	Active, Not Recruiting	A 2-part study to assess safety, tolerability, and PK of multiple doses in ALS patients, followed by a long-term active treatment extension. 25
NCT05740813	Phase 2/3	Amyotrophic Lateral Sclerosis (ALS)	Completed	Regimen F of the HEALEY ALS Platform Trial, evaluating the efficacy and safety of two doses of Fosigotifator versus placebo over 24 weeks. 11
NCT05757141	Phase 1/2	Vanishing White Matter (VWM) Disease	Recruiting	An open-label study to evaluate safety, tolerability, PK, and exploratory efficacy in adult and pediatric patients with VWM. 9
NCT06618118	Phase 1	Major Depressive Disorder (MDD)	Recruitment Complete	A double-blind, placebo-controlled study to evaluate the safety and efficacy of Fosigotifator in adults with MDD. 18
NCT06425003	Phase 1	Healthy Volunteers	Completed	A study using radiolabeled $[^{14}C]$ ABBV-CLS-7262 to characterize ADME in healthy male volunteers. 21
NCT05763459	Phase 1	Healthy Volunteers	Completed	An open-label study to evaluate drug-drug interactions between ABBV-CLS-7262, rosuvastatin, and digoxin. 22

Indication I: Amyotrophic Lateral Sclerosis (ALS)

ALS, a devastating and fatal neurodegenerative disease, was the first patient population in which Fosigotifator was tested and represented the most advanced part of its clinical program.

Early Phase Development (NCT04948645)

The initial foray into patients was a Phase 1 study (NCT04948645) designed primarily to establish the safety, tolerability, and pharmacokinetics of multiple doses of Fosigotifator in individuals with ALS.[25] The study enrolled 31 participants and featured a two-part design: Part 1 was a 4-week, randomized, double-blind, placebo-controlled period, which was followed by Part 2, a long-term (up to 152-week) active treatment extension in which all participants received Fosigotifator.[25] According to ClinicalTrials.gov, the study is "Active, not recruiting," suggesting that the initial randomized phase is complete and participants have transitioned into the long-term extension.[26] Preliminary safety information from this ongoing study indicated that the most frequent adverse events possibly related to the drug were generally mild, including nausea (10%), itchiness (7%), constipation (7%), dizziness (7%), and headache (7%).[17] It is important to note that this data was from the blinded phase and may include events from patients who received a placebo.[17]

The HEALEY ALS Platform Trial (Regimen F, NCT05740813)

Building on the initial safety data, Fosigotifator was selected as Regimen F for the HEALEY ALS Platform Trial, a perpetual, multi-center, multi-regimen study designed to accelerate the evaluation of promising new therapies for ALS.[11] This large-scale Phase 2/3 study randomized participants in a 3:1 ratio to receive either active drug or a matching placebo, administered orally once daily for 24 weeks.[23]

The trial was designed to evaluate two different dose levels of Fosigotifator. A total of 155 participants were randomized to the primary dose, and an additional 79 were randomized to an exploratory high dose. The outcomes for these groups were compared against a shared concurrent placebo cohort of 126 participants.[29] The primary endpoint was a composite measure of disease progression, using a joint model of the change in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score and survival over the 24-week treatment period.[23] Key secondary endpoints included changes in muscle strength, as measured by hand-held dynamometry (HHD), and respiratory function, as measured by Slow Vital Capacity (SVC).[23]

In-Depth Analysis: Reconciling Primary Endpoint Failure with Positive Signals in Muscle Strength

The topline results from the HEALEY ALS trial, announced in early 2025, presented a complex and dichotomous outcome that represents a critical inflection point for the entire Fosigotifator program.

At the pre-specified primary dose, the trial was an unambiguous failure. It did not meet its primary endpoint, showing no statistically significant difference in the rate of functional decline or survival compared to the placebo group.[13] The key secondary endpoints of respiratory function and muscle strength also showed no benefit at this dose.[13]

However, the trial's design included a pre-specified analysis of an exploratory high dose, and the results from this cohort told a very different story. While this higher dose also did not meet the composite primary endpoint, it demonstrated statistically significant and potentially clinically meaningful effects on the direct measure of muscle strength preservation. The decline in muscle strength, as measured by HHD, was substantially slower in patients receiving the high dose of Fosigotifator compared to placebo. This effect was observed in both upper and lower extremities. Additionally, a non-significant trend, described as a "potential signal," towards a slowing of respiratory decline was also observed in the high-dose group.[29]

This divergence in outcomes strongly suggests a dose-dependent effect of Fosigotifator, with the primary dose being therapeutically insufficient and the higher dose crossing a threshold for biological activity. The failure of the primary endpoint is a major setback, but the statistically robust signal on a key functional measure like muscle strength, which was enabled by the drug's excellent safety profile, prevents an outright declaration of failure. The future of the ALS program now depends entirely on whether the developers will pursue a new, pivotal trial designed to confirm these promising high-dose findings. The detailed results are summarized in Table 3.

Endpoint	Primary Dose vs. Placebo	Exploratory High Dose vs. Placebo
Primary Endpoint (ALSFRS-R + Survival)	Not Met (No significant difference) 13	Not Met (No significant difference) 13
Secondary Endpoint: Muscle Strength (HHD) - Upper Extremities	Not Met (No significant difference) 29	32% slower decline (vs. shared placebo, nominal p=0.014) 29
Secondary Endpoint: Muscle Strength (HHD) - Lower Extremities	Not Met (No significant difference) 29	62% slower decline (vs. shared placebo, nominal p=0.037) 29
Secondary Endpoint: Respiratory Function (SVC)	Not Met (No significant difference) 29	Potential signal towards slowing decline (Not statistically significant) 29

Indication II: Vanishing White Matter (VWM) Disease

In contrast to the complex pathophysiology of ALS, the VWM program for Fosigotifator is built on a direct and compelling mechanistic foundation, positioning it as the asset with the highest probability of success.

Rationale and Study Design (NCT05757141)

VWM disease is an ultra-rare, progressive, and fatal leukoencephalopathy caused by mutations in the genes encoding the eIF2B enzyme.[9] This provides a perfect, mechanism-based rationale for treatment with an eIF2B activator like Fosigotifator, which is designed to directly compensate for the genetic defect.[9]

A Phase 1b/2 clinical trial (NCT05757141) is currently underway to evaluate the drug in this population. It is an open-label, single-arm study designed to assess the safety, tolerability, pharmacokinetics, and exploratory efficacy of Fosigotifator in both adult and pediatric participants (aged 6 months and older) with a genetically confirmed diagnosis of VWM.[9] The study, which is currently recruiting, plans to enroll approximately 50 participants and will follow them for up to 201 weeks.[9] The primary outcome measures are focused on establishing safety and characterizing drug concentrations in the initial weeks of treatment, while long-term exploratory efficacy will be assessed through measures such as changes in brain MRI.[9]

Regulatory Context and Potential: The FDA START Pilot Program

The significant potential of Fosigotifator in VWM was recognized by regulatory authorities. In June 2024, the U.S. FDA selected Fosigotifator for its START (Support for clinical Trials Advancing Rare disease Therapeutics) Pilot Program for the VWM indication.[20] This highly selective program is intended to accelerate the development of promising therapies for rare diseases by providing the sponsor with enhanced and more frequent communication with FDA review staff. This collaborative framework allows for proactive discussion and optimization of critical development issues, such as clinical study design, choice of control groups, and patient population selection, potentially streamlining the path to approval.[36] This designation is a major vote of confidence from the FDA and a significant de-risking event for the VWM program.

Indication III: Major Depressive Disorder (MDD)

The investigation of Fosigotifator in MDD represents a bold, exploratory expansion of the ISR therapeutic hypothesis into the realm of psychiatric disorders.

Scientific Premise and Early Clinical Exploration (NCT06618118)

The scientific premise for this indication is based on a growing body of evidence linking chronic cellular stress and the subsequent activation of the ISR to the underlying pathophysiology of depression.[18] To test this hypothesis, AbbVie initiated a Phase 1 study (M24-840; NCT06618118) to obtain an initial reading on the safety and efficacy of Fosigotifator in this new population.[18]

The study is a double-blind, placebo-controlled trial that enrolled approximately 106 adult participants with MDD. The treatment duration is approximately 144 days, and the primary objective is to evaluate the safety profile by measuring the number of participants who experience adverse events.[18] Recruitment for this initial exploratory study is now complete, and the results will be critical in determining whether this indication is pursued further.[18]

Comprehensive Safety and Tolerability Profile

Across a comprehensive clinical program involving healthy volunteers and patients with multiple neurological conditions, Fosigotifator has consistently demonstrated an exceptionally favorable safety and tolerability profile. This benign profile is a major strategic asset for the drug, as it provides significant flexibility for dose exploration and long-term administration.

In the initial Phase 1 studies in healthy volunteers, ABBV-CLS-7262 was administered to over 125 subjects at single and multiple ascending doses. The drug was found to be well-tolerated, with all reported adverse events being mild to moderate in severity. Crucially, no dose-limiting toxicities or concerning patterns in laboratory tests were identified, establishing a wide therapeutic window from the outset.[10]

This favorable safety profile was maintained when the drug was introduced into patient populations. In the Phase 1b study in patients with ALS (NCT04948645), preliminary data from the blinded portion of the trial indicated that the most common adverse events potentially attributable to the drug were mild and included nausea, pruritus (itchiness), constipation, dizziness, and headache.[17]

The most robust safety data comes from the large Phase 2/3 HEALEY ALS Platform Trial, which involved hundreds of patients treated for 24 weeks. The results from this study confirmed the excellent safety profile observed in earlier trials.

• Overall, Fosigotifator was found to be safe and well-tolerated, with no meaningful safety differences observed between the active drug and placebo groups, or between the primary and the exploratory high doses.[30]
• The rates of treatment-emergent adverse events (TEAEs) were nearly identical, occurring in 90.6% of participants in the combined Fosigotifator groups and 89.7% of participants in the shared placebo group.[29]
• Perhaps most strikingly, the rate of TEAEs that were considered by investigators to be related to the study drug was actually slightly lower in the Fosigotifator group (25.2%) than in the placebo group (26.2%).[29]

This placebo-like safety profile is not merely a footnote; it is a core feature of the drug that has had a direct impact on its development trajectory. It was this excellent tolerability that enabled the inclusion of an exploratory high dose in the HEALEY trial without raising undue safety concerns. The subsequent discovery of a promising efficacy signal only at this higher dose means that the drug's benign safety profile was the key factor that kept the ALS program viable after the failure of the primary dose. This favorable safety record provides the developers with significant latitude for dose selection in future trials across all indications.

Synthesis, Strategic Analysis, and Future Outlook

Fosigotifator (ABBV-CLS-7262) is a scientifically compelling, first-in-class therapeutic candidate targeting the fundamental Integrated Stress Response pathway. Its development, a product of the strategic partnership between Calico Life Sciences and AbbVie, has been characterized by rigorous early-phase science, a bold multi-indication strategy, and a pivotal, complex outcome in its most advanced clinical trial. The program is now at a critical crossroads, where the interpretation of recent results and subsequent strategic decisions will determine the ultimate fate of this novel asset.

Current State of Development

The journey of Fosigotifator has been one of scientific validation followed by clinical challenge. The early pharmacology program was a model of efficiency, successfully demonstrating that the oral drug could penetrate the central nervous system and engage its eIF2B target in humans. However, the subsequent Phase 2/3 HEALEY ALS Platform Trial delivered a major setback: the drug failed to meet its primary endpoint at the primary dose. This result was partially offset by the pre-specified finding of statistically significant and potentially meaningful preservation of muscle strength at an exploratory high dose. The program is therefore not a complete failure, but rather one that has generated a clear, data-driven hypothesis that requires further, high-risk validation. In parallel, the program in the ultra-rare VWM disease has emerged as the clear lead indication, buoyed by an impeccable mechanistic rationale and favorable regulatory support from the FDA. The foray into MDD remains an early-stage, high-risk exploration.

The Calico/AbbVie Strategy

The development of Fosigotifator is a direct reflection of the unique mission of its originators. Calico was founded to understand the fundamental biology of aging, and its partnership with AbbVie is designed to translate that knowledge into therapies for age-related diseases.[2] The ISR is a core pathway involved in maintaining cellular homeostasis and resilience, processes that become dysregulated with age. The decision to investigate Fosigotifator across neurodegeneration (ALS, VWM) and psychiatry (MDD) is a deliberate test of the grand hypothesis that modulating the ISR can be a unifying therapeutic strategy for a range of chronic diseases. The VWM program, where the disease is directly caused by a defect in the drug's target, serves as the most direct and elegant test of this hypothesis. Success in VWM would provide powerful validation for the entire platform and could reinvigorate the more ambitious applications in ALS and MDD.

Future Outlook and Unanswered Questions

The future of Fosigotifator will be determined by a series of key decisions and data readouts in the coming years.

• Amyotrophic Lateral Sclerosis (ALS): The central question is whether AbbVie and Calico will commit the substantial resources required to conduct a new Phase 3 trial in ALS. Such a trial would need to be designed specifically around the exploratory high dose and would likely need to incorporate muscle function (HHD) as a primary or key secondary endpoint. The decision will undoubtedly hinge on a full analysis of the biomarker and long-term extension data from the HEALEY trial, as well as the partnership's strategic appetite for a high-risk, high-reward investment in this challenging disease area.
• Vanishing White Matter (VWM) Disease: This program is now the undisputed priority and holds the key to the drug's future. The direct genetic link between the disease and the drug's target, combined with the support of the FDA's START program, creates the clearest path to a first potential approval. The critical upcoming milestones will be the completion of enrollment in the Phase 1b/2 study (NCT05757141) and the subsequent data readouts on safety, pharmacokinetics, and exploratory efficacy markers like brain MRI changes. A positive outcome in this trial would be a transformative event for the entire Fosigotifator program.
• Major Depressive Disorder (MDD): This indication remains in an early, exploratory phase. The future of the MDD program is entirely dependent on the results from the recently completed Phase 1 safety and efficacy study (NCT06618118). A clear signal of therapeutic activity would be needed to justify advancing to larger, more definitive Phase 2 trials.

Final Assessment

In conclusion, Fosigotifator remains a highly innovative asset with a validated mechanism of action, confirmed CNS penetration and target engagement in humans, and an exceptionally favorable safety profile. The failure to meet the primary endpoint in the ALS trial was a significant disappointment, but the positive, dose-dependent signals on muscle strength provide a clear, data-driven rationale for continued investigation, albeit with a higher risk profile. The drug's ultimate success and the validation of the ISR as a therapeutic target will likely be decided by the outcome of the ongoing trial in Vanishing White Matter disease. This indication represents the most mechanistically sound application of this novel therapeutic approach and stands as the program's best and most immediate opportunity to deliver a transformative new medicine for patients with a devastating and currently untreatable disease.

Works cited

1. Fosigotifator sodium tromethamine | C29H37Cl2F2N3NaO12P | CID ..., accessed October 23, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Abbv-cls-7262
2. Fosigotifator - Wikipedia, accessed October 23, 2025, https://en.wikipedia.org/wiki/Fosigotifator
3. Fosigotifator | C25H27Cl2F2N2O9P | CID 153563259 - PubChem, accessed October 23, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Fosigotifator
4. Fosigotifator: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 23, 2025, https://go.drugbank.com/drugs/DB19409
5. ABBV-CLS-7262: Uses, Interactions, Mechanism of Action ..., accessed October 23, 2025, https://go.drugbank.com/drugs/DB18407
6. fosigotifator | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 23, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12886
7. www.guidetopharmacology.org, accessed October 23, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=refs&ligandId=12886
8. Phase 1 Asian PK Study of ABBV-CLS-7262, an eIF2B Activator Being Developed as a Potential Treatment for Amyotrophic Lateral Sclerosis and Vanishing White Matter Disease (P5-11.014) - Neurology.org, accessed October 23, 2025, https://www.neurology.org/doi/10.1212/WNL.0000000000205702
9. Calico Life Sciences Announces First Participant Dosed in Phase 1b ..., accessed October 23, 2025, https://www.calicolabs.com/press/calico-life-sciences-announces-first-participant-dosed-in-phase-1b-clinical-study-evaluating-abbv-cls-7262-for-the-treatment-of-vanishing-white-matter-disease/
10. A Phase 1 First-in-human Study to Investigate the Safety, Tolerability and Food Effect of ABBV-CLS-7262 (P6-4.002) - Neurology.org, accessed October 23, 2025, https://www.neurology.org/doi/10.1212/WNL.0000000000203810
11. The HEALEY ALS Platform Trial completes enrollment for testing investigational product ABBV-CLS-7262 from Calico Life Sciences - Massachusetts General Hospital, accessed October 23, 2025, https://www.massgeneral.org/neurology/als/news/abbv-cls-7262-completes-enrollment
12. Investigational drug ABBV-CLS-7262 initiates design phase for entry into the HEALEY ALS Platform Trial - Massachusetts General Hospital, accessed October 23, 2025, https://www.massgeneral.org/news/press-release/investigational-drug-initiates-design-phase-for-healey-als-trial
13. Calico Provides Update on Fosigotifator in HEALEY ALS Platform Trial, accessed October 23, 2025, https://www.calicolabs.com/press/calico-statement-on-fosigotifator-in-healey-als-platform-trial/
14. Clinical Trial: Vanishing White Matter - Calico, accessed October 23, 2025, https://www.calicolabs.com/clinical-trial-vanishing-white-matter/
15. Fosigotifator - AbbVie/Calico - AdisInsight - Springer, accessed October 23, 2025, https://adisinsight.springer.com/drugs/800064446
16. Fosigotifator | CAS#2415715-84-1 | eIF2B activator - MedKoo Biosciences, accessed October 23, 2025, https://www.medkoo.com/products/55542
17. ABBV-CLS-7262 for ALS, accessed October 23, 2025, https://www.massgeneral.org/assets/mgh/pdf/neurology/als/regimenf_calicosabbv-cls-7262drugsciencewebinar_2023.pdf
18. A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262 ..., accessed October 23, 2025, https://www.abbvieclinicaltrials.com/study/?id=M24-840
19. ABBV-CLS-7262 (Fosigotifator THAM sodium) | Eukaryotic Initiation Factor (eIF) Activator, accessed October 23, 2025, https://www.medchemexpress.com/abbv-cls-7262.html
20. Calico Life Sciences Announces that Fosigotifator (ABBV-CLS-7262) for Vanishing White Matter Disease has been Selected for the FDA START Pilot Program, accessed October 23, 2025, https://www.calicolabs.com/press/calico-life-sciences-announces-that-fosigotifator-abbv-cls-7262-for-vanishing-white-matter-disease-has-been-selected-for-the-fda-start-pilot-program/
21. Healthy Subjects (HS) Completed Phase 1 Trials for ABBV-CLS-7262 (DB18407), accessed October 23, 2025, https://go.drugbank.com/indications/DBCOND0132512/clinical_trials/DB18407?phase=1&status=completed
22. NCT05763459 | A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects | ClinicalTrials.gov, accessed October 23, 2025, https://www.clinicaltrials.gov/study/NCT05763459
23. Study Details | NCT05740813 | HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262 | ClinicalTrials.gov, accessed October 23, 2025, https://www.clinicaltrials.gov/study/NCT05740813?term=ALS&cond=Amyotrophic%20lateral%20sclerosis&aggFilters=funderType:industry&viewType=Table&rank=7
24. HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262 | Clinical Research Trial Listing, accessed October 23, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT05740813/healey-als-platform-trial-regimen-f-abbv-cls-7262
25. A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of ABBV-CLS-7262 in Subjects With Amyotrophic Lateral Sclerosis Followed by an Active Treatment Extension | NEALS, accessed October 23, 2025, https://neals.org/als-trials/nct04948645
26. NCT04948645 | A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis | ClinicalTrials.gov, accessed October 23, 2025, https://www.clinicaltrials.gov/study/NCT04948645
27. NCT05757141 | An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease | ClinicalTrials.gov, accessed October 23, 2025, https://clinicaltrials.gov/study/NCT05757141
28. A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis - Abbvie Clinical Trials, accessed October 23, 2025, https://www.abbvieclinicaltrials.com/study/?id=M20-405
29. Topline results in Healey ALS Platform Trial with AbbVie – Calico eIF2B activator Fosigotifator - EUpALS, accessed October 23, 2025, https://als.eu/sites/default/files/topline_results_abbvie_-_calico_eif2b_activator_fosigotifator.pdf
30. Sean M. Healey & AMG Center Announces Update in ALS Platform ..., accessed October 23, 2025, https://www.massgeneral.org/neurology/als/news/healeyamg-announces-platform-trial-update-fosigotifator
31. ALS investigational therapies DNL343 and fosigotifator fail HEALEY trial goals, accessed October 23, 2025, https://alsnewstoday.com/news/als-investigational-therapies-dnl343-fosigotifator-fail-healey-trial-goals/
32. Calico draws blank in study of AbbVie-partnered drug for ALS - FirstWord Pharma, accessed October 23, 2025, https://firstwordpharma.com/story/5925444
33. Fosigotifator Fails to Meet End Points in HEALEY-ALS Platform Trial | NeurologyLive, accessed October 23, 2025, https://www.neurologylive.com/view/fosigotifator-fails-to-meet-end-points-in-healey-als-platform-trial
34. An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease - Abbvie Clinical Trials, accessed October 23, 2025, https://www.abbvieclinicaltrials.com/study/?id=M23-523
35. Vanishing White Matter Disease Recruiting Phase 1 Trials for ABBV-CLS-7262 (DB18407), accessed October 23, 2025, https://go.drugbank.com/indications/DBCOND0092548/clinical_trials/DB18407?phase=1&status=recruiting
36. Calico Life Sciences Announces that Fosigotifator (ABBV-CLS-7262 ..., accessed October 23, 2025, https://www.prnewswire.com/news-releases/calico-life-sciences-announces-that-fosigotifator-abbv-cls-7262-for-vanishing-white-matter-disease-has-been-selected-for-the-fda-start-pilot-program-302166753.html
37. Calico (company) - Wikipedia, accessed October 23, 2025, https://en.wikipedia.org/wiki/Calico_(company)
38. Calico and AbbVie Share Update on Early-Stage Clinical Programs ..., accessed October 23, 2025, https://www.calicolabs.com/press/calico-and-abbvie-share-update-on-early-stage-clinical-programs/